Grown Rogue enters NY via JV, $15M financing commitment, plans PharmaCann NY acquisition

Grown Rogue International Inc.

Grown Rogue New York JV: capital partner invests $10M for 49% preferred equity; Grown Rogue holds 51%.
Planned purchase price ~$4.5M ($3M at regulatory approval); plus $5M drawable term loan at 15%, $9M secured loan to PCNY.
Targets: 4 Verilife dispensaries (avg $1.7-2.0M monthly sales) and Hamptonburgh facility with 24,000 sq ft indoor + 16,000 sq ft greenhouse canopy.
Preferred equity convertible to ~18.2M SVS (~7% dilution) at $0.55-0.76/share; commitment fee 300K shares + 0.901 warrants per $1 drawn.
Expects NY operations cash-flow positive within 9 months, ~$600K monthly after-tax CF within 18 months; ~$20M annual cost reductions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.